SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS WITH INADEQUATE RESPONSE TO TNF INHIBITORS

被引：1

作者：

Fleischmann, R. ^{[1
]}

Hrycaj, P. ^{[2
]}

van Hoogstraten, H. ^{[3
]}

Mangan, E. K. ^{[4
]}

Lin, Y. ^{[3
]}

Jayawardena, S. ^{[3
]}

Burmester, G. R. ^{[5
,6
]}

机构：

[1] Univ Texas Southwestern Med Ctr Dallas, Metroplex Clin Res Ctr, Dallas, TX 75390 USA

[2] Poznan Univ Med Sci, Dept Rheumatol & Clin Immunol, Poznan, Poland

[3] Sanofi Genzyme, Bridgewater, MA USA

[4] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[5] Free Univ, Charite Univ Med Berlin, Berlin, Germany

[6] Humboldt Univ, Berlin, Germany

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷

关键词：

D O I：

10.1136/annrheumdis-2017-eular.5155

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

SAT0212

引用

页码：853 / 853

页数：1

共 50 条

[1] Sarilumab Dose Reduction in an Open-Label Extension Study in RA Patients
Genovese, Mark C.
Fay, Jon
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
Graham, Neil
Boddy, Alex
Simon, J-Abraham
Martincova, Renata
Burmester, Gerd R.
ARTHRITIS & RHEUMATOLOGY, 2016, 68
[2] Sarilumab Dose Reduction in an Open-label Extension Study in RA Patients
Genovese, Mark
Fay, Jonathan
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
van Hoogstraten, Hubert
Graham, Neil
Boddy, Alex
Simon, Abraham
Martincova, Renata
Burmester, Gerd
Fiore, Stefano
JOURNAL OF RHEUMATOLOGY, 2017, 44 (06) : 895 - 896
[3] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Genovese, M. C.
Fay, J.
Beyer, D.
Iglesias-Rodriguez, M.
Simon, A.
Martincova, R.
Burmester, G. R.
JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2018, 24 : S69 - S70
[4] SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Genovese, M. C.
Fay, J.
Parrino, J.
Garg, A.
Van Hoogstraten, H.
Boddy, A.
Martincova, R.
Graham, N.
Simon, J.
Burmester, G. R.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 515 - 516
[5] Sarilumab Dose Reduction to Manage Laboratory Abnormalities in an Open-Label Extension Study in RA Patients
Burmester, Gerd
Garg, Anju
van Hoogstraten, Hubert
Graham, Neil
Boddy, Alex
Parrino, Janie
Genovese, Mark C.
ARTHRITIS & RHEUMATOLOGY, 2015, 67
[6] SARILUMAB DOSE REDUCTION TO MANAGE LABORATORY ABNORMALITIES IN AN OPEN-LABEL EXTENSION STUDY IN RA PATIENTS
Burmester, Gerd R.
Garg, Anju
Van Hoogstraten, Hubert
Graham, Neil
Boddy, Alexander
Parrino, Janie
Genovese, Mark C.
INTERNAL MEDICINE JOURNAL, 2016, 46 : 40 - 41
[7] SARILUMAB DOSE REDUCTION IN AN OPEN-LABEL EXTENSION STUDY IN RHEUMATOID ARTHRITIS PATIENTS
Genovese, Mark C.
Fay, Jon
Parrino, Janie
Beyer, Doris
Iglesias-Rodriguez, Melitza
Graham, Neil
Boddy, Alex
Martincova, Renata
Burmester, Gerd R.
RHEUMATOLOGY, 2017, 56 : 139 - 139
[8] Glucocorticoid Dose Is Progressively Reduced in Patients with RA Receiving Sarilumab: Results from the Open-Label EXTEND Study
Fleischmann, Roy
Selmi, Carlo
Gonzalez-Gay, Miguel Angel
van Hoogstraten, Hubert
Hagino, Owen
Rajput, Tejasweeni
St John, Gregory
Buttgereit, Frank
Genovese, Mark
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[9] Tocilizumab in Patients with Active Rheumatoid Arthritis and Inadequate Response to DMARDs and/or TNF Inhibitors: A Large, Open-Label Study Close to Clinical Practice
Lunzer, R.
JOURNAL FUR MINERALSTOFFWECHSEL, 2012, 19 (04): : 195 - 195
[10] Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice
Bykerk, Vivian P.
Ostor, Andrew J. K.
Alvaro-Gracia, Jose
Pavelka, Karel
Ivorra, Jose Andres Romon
Graninger, Winfried
Bensen, William
Nurmohamed, Michael T.
Krause, Andreas
Bernasconi, Corrado
Stancati, Andrea
Sibilia, Jean
ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (12) : 1950 - 1954

← 1 2 3 4 5 →